CN116368141B - 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途 - Google Patents
噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途Info
- Publication number
- CN116368141B CN116368141B CN202180067894.4A CN202180067894A CN116368141B CN 116368141 B CN116368141 B CN 116368141B CN 202180067894 A CN202180067894 A CN 202180067894A CN 116368141 B CN116368141 B CN 116368141B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- formula
- ampk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015585.9A GB202015585D0 (en) | 2020-10-01 | 2020-10-01 | New compounds |
| GB2015585.9 | 2020-10-01 | ||
| PCT/GB2021/052535 WO2022069894A1 (en) | 2020-10-01 | 2021-09-30 | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116368141A CN116368141A (zh) | 2023-06-30 |
| CN116368141B true CN116368141B (zh) | 2025-09-23 |
Family
ID=73223766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180067894.4A Active CN116368141B (zh) | 2020-10-01 | 2021-09-30 | 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230382930A1 (https=) |
| EP (1) | EP4222147B1 (https=) |
| JP (1) | JP7793614B2 (https=) |
| KR (1) | KR20230079163A (https=) |
| CN (1) | CN116368141B (https=) |
| AU (1) | AU2021352146A1 (https=) |
| CA (1) | CA3193947A1 (https=) |
| ES (1) | ES3018732T3 (https=) |
| GB (1) | GB202015585D0 (https=) |
| HU (1) | HUE071685T2 (https=) |
| MX (1) | MX2023003825A (https=) |
| PL (1) | PL4222147T3 (https=) |
| WO (1) | WO2022069894A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202112529D0 (en) * | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| EP4600642A1 (en) * | 2022-10-05 | 2025-08-13 | Sawai Pharmaceutical Co., Ltd. | Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
-
2020
- 2020-10-01 GB GBGB2015585.9A patent/GB202015585D0/en not_active Ceased
-
2021
- 2021-09-30 CN CN202180067894.4A patent/CN116368141B/zh active Active
- 2021-09-30 HU HUE21816508A patent/HUE071685T2/hu unknown
- 2021-09-30 WO PCT/GB2021/052535 patent/WO2022069894A1/en not_active Ceased
- 2021-09-30 EP EP21816508.2A patent/EP4222147B1/en active Active
- 2021-09-30 CA CA3193947A patent/CA3193947A1/en active Pending
- 2021-09-30 JP JP2023520459A patent/JP7793614B2/ja active Active
- 2021-09-30 ES ES21816508T patent/ES3018732T3/es active Active
- 2021-09-30 US US18/028,192 patent/US20230382930A1/en active Pending
- 2021-09-30 MX MX2023003825A patent/MX2023003825A/es unknown
- 2021-09-30 AU AU2021352146A patent/AU2021352146A1/en active Pending
- 2021-09-30 PL PL21816508.2T patent/PL4222147T3/pl unknown
- 2021-09-30 KR KR1020237014527A patent/KR20230079163A/ko active Pending
Non-Patent Citations (1)
| Title |
|---|
| Non-ATP competitive glycogen synthase kinase 3β(GSK-3β) inhibitors: Study of structural requirements for thiadiazolidinone derivatives;Ana Castro et al.;Bioorganic & Medicinal Chemistry;20070917;第16卷(第1期);第495-510页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3193947A1 (en) | 2022-04-07 |
| HUE071685T2 (hu) | 2025-09-28 |
| JP7793614B2 (ja) | 2026-01-05 |
| CN116368141A (zh) | 2023-06-30 |
| ES3018732T3 (en) | 2025-05-19 |
| PL4222147T3 (pl) | 2025-06-09 |
| EP4222147C0 (en) | 2025-03-19 |
| JP2023543924A (ja) | 2023-10-18 |
| EP4222147A1 (en) | 2023-08-09 |
| AU2021352146A1 (en) | 2023-06-01 |
| MX2023003825A (es) | 2023-06-06 |
| EP4222147B1 (en) | 2025-03-19 |
| GB202015585D0 (en) | 2020-11-18 |
| WO2022069894A1 (en) | 2022-04-07 |
| KR20230079163A (ko) | 2023-06-05 |
| US20230382930A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| CN116368141B (zh) | 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途 | |
| EP2703396B1 (en) | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | |
| JP7697885B2 (ja) | 化合物の製剤およびそれらの使用 | |
| US20230109134A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| CN111635315B (zh) | 一种解热镇痛药物及其制备方法和用途 | |
| US20260001872A1 (en) | Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof | |
| US20150376216A1 (en) | Sugar-analog phosphorus-containing heterocycles having an anti-metastatic activity | |
| JP2024535745A (ja) | Ａｍｐｋ活性化剤として有用なチアジアゾロン誘導体 | |
| US12522628B2 (en) | Aryl glucoside derivative and use thereof in drug | |
| HK40092998A (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| HK40092998B (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| CN106432026A (zh) | 一类对糖尿病具有潜在治疗活性的化合物 | |
| WO2008047769A1 (en) | Glucose metabolism ameliorating agent | |
| EA000166B1 (ru) | Биологически активные уреидо-производные, полезные при лечении рассеянного склероза | |
| WO2010098298A1 (ja) | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 | |
| KR20190090729A (ko) | 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| KR20260037952A (ko) | 육산화사비소를 유효성분으로 포함하는 대사이상 관련 지방간질환 치료 또는 예방용 조성물 | |
| US20230365610A1 (en) | Aryl Glucoside Derivative | |
| CN121627598A (zh) | 一种嘧啶-2-苯胺衍生物及其合成方法和应用 | |
| WO2025099561A1 (en) | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JPH09227529A (ja) | ニトロイミダゾール誘導体 | |
| WO2021036495A1 (zh) | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 | |
| JPH1025280A (ja) | ニトロイミダゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20241031 Address after: Swedish chicken Applicant after: BETAGENON AB Country or region after: Sweden Address before: Swedish chicken Applicant before: Betajinon Bio Country or region before: Sweden |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |